SCHEMBL21831876

SCHEMBL21831876

NC(=O)C1CN(C(=O)O)CCN1C(c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 5/20 0.43
CACNA1B Q00975 3/20 0.42
CACNA2D1 P54289 1/20 0.42
CACNB1 Q02641 1/20 0.42
CACNA1C Q13936 1/20 0.42
DPP7 Q9UHL4 3/20 0.40
LMNA P02545 1/20 0.39
FAAH O00519 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39
MAPK1 P28482 1/20 0.39
MTOR P42345 1/20 0.39
RAB9A P51151 1/20 0.39
MGLL Q99685 1/20 0.38
DPP4 P27487 3/20 0.38
MEN1 O00255 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30910913 0.89 CACNA1B (0.44) DPP8CACNA1BCACNA2D1CACNB1CACNA1C
SCHEMBL21831121 0.82 DPP8 (0.57) DPP8CACNA1BCACNA2D1CACNB1CACNA1C
SCHEMBL21831233 0.82 DPP8 (0.57) DPP8CACNA1BCACNA2D1CACNB1CACNA1C
SCHEMBL21831122 0.82 DPP8 (0.57) DPP8CACNA1BCACNA2D1CACNB1CACNA1C
SCHEMBL21831049 0.82 NPC1 (0.42) DPP8DPP7LMNAMAPK1RAB9A
SCHEMBL21831199 0.81 CNR1 (0.43) DPP8CACNA1BCACNA2D1CACNB1CACNA1C
SCHEMBL28560503 0.80 DPP8 (0.40) DPP8CACNA1BCACNA2D1CACNB1CACNA1C
SCHEMBL21831289 0.80 DPP8 (0.43) DPP8CACNA1BCACNA2D1CACNB1CACNA1C
SCHEMBL21831290 0.80 DPP8 (0.43) DPP8CACNA1BCACNA2D1CACNB1CACNA1C
SCHEMBL21831360 0.80 DPP8 (0.43) DPP8CACNA1BCACNA2D1CACNB1CACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814348-B9 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-11-01 EP disclosed
EP-3814348-B1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 EP disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 US disclosed
EP-3814348-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS Bristol-Myers Squibb Company (US) 2021-05-05 EP disclosed
US-10954238-B1 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2021-03-23 US disclosed
US-10669272-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-02 US disclosed
US-20200109140-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2020-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109140-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG DPP8 3019/4885CACNA1B 2544/4885CACNA2D1 1650/4885
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG DPP8 3019/4885CACNA1B 2544/4885CACNA2D1 1650/4885
US-10669272-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG DPP8 3019/4885CACNA1B 2544/4885CACNA2D1 1650/4885
US-10954238-B1 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG DPP8 3019/4885CACNA1B 2544/4885CACNA2D1 1650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.